Compression Therapy Market Size, Share & Forecast 2026-2033

Overview

The global compression therapy market was valued at USD 4.5 billion in 2025 and is expected to reach USD 7 billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033). Compression therapy involves the use of elastic garments and medical devices, including compression stockings, bandages, wraps, and intermittent pneumatic compression systems, to improve venous and lymphatic circulation, reduce swelling, prevent deep vein thrombosis (DVT), and manage conditions such as chronic venous insufficiency, lymphedema, varicose veins, and leg ulcers. The therapy has become a standard component of post-operative care, chronic disease management, and home-based treatment across hospitals, clinics, and outpatient settings.

Market growth is primarily driven by demographic aging, increasing prevalence of venous and lymphatic disorders, rising orthopedic procedure volumes, and the growing shift toward home-based healthcare. According to the World Health Organization (WHO), one in six people worldwide will be aged 60 years or older by 2030, with the global elderly population projected to reach 2.1 billion by 2050. Since advancing age significantly increases the risk of chronic venous insufficiency, varicose veins, lymphedema, and deep vein thrombosis, the expanding elderly population is creating sustained demand for compression therapy products. At the same time, increasing knee and hip replacement procedures, together with greater awareness of post-operative DVT prevention, continue to support broader adoption of compression garments and pneumatic compression devices.

The growing clinical burden further reinforces market expansion. According to the U.S. Centers for Disease Control and Prevention (CDC), DVT affects up to 900,000 people annually in the United States. Incidence rates increase substantially with age, while rising diabetes prevalence and sedentary lifestyles are contributing to higher rates of venous and vascular disorders across both developed and emerging markets. Healthcare providers are increasingly adopting compression therapy to improve circulation, reduce edema, accelerate wound healing, and enhance long-term patient outcomes across hospital and home-care settings.

Technological innovation is also reshaping the market through the introduction of smart pneumatic compression systems, wearable monitoring capabilities, personalized pressure management, and AI-enabled compression technologies that improve treatment effectiveness and patient adherence. Manufacturers are focusing on lighter, more comfortable, and digitally connected products that support remote patient monitoring and long-term home use. For example, in November 2024, Cardinal Health launched the Kendall SCD SmartFlow Compression System, an advanced intermittent pneumatic compression platform designed to enhance venous thromboembolism prevention while improving patient comfort and clinical efficiency.

Despite favorable growth prospects, the market continues to face challenges related to low patient adherence, inconsistent reimbursement policies, and the mature penetration of traditional compression garments in several developed markets. Nevertheless, demographic aging, increasing chronic disease prevalence, expanding home healthcare, continuous technological innovation, and growing adoption of connected compression therapy solutions are expected to support sustained growth of the global compression therapy market through 2033.

Drivers

Growing Number of Orthopedic Procedures

The growing number of orthopedic procedures is a key factor driving the expansion of the compression therapy market size. As surgeries such as knee and hip replacements become more common, particularly among older patients, the demand for effective post-operative care solutions, including compression therapy, is rising sharply. Compression bandages and devices are widely used after orthopedic surgeries to prevent complications such as deep vein thrombosis (DVT), reduce post-operative swelling, and support venous return, all of which are critical for promoting faster and safer recovery.

According to the American College of Rheumatology, the U.S. performs approximately 790,000 knee replacements and 544,000 hip replacements each year, a number that continues to grow with the aging population. Similarly, in Australia, the Australian Orthopedic Association National Joint Replacement Registry (AOANJRR) reported in 2024 that more than 2.1 million orthopedic procedures had been conducted. These figures reflect a global trend of increasing joint replacement surgeries, driven not only by demographic shifts but also by advancements in surgical techniques and improved access to orthopedic care.

In response to this growing need, innovations in compression therapy are emerging to enhance patient outcomes and simplify care. A notable development came in November 2024, when scientists from the University of Edinburgh introduced a low-cost, flexible device designed to prevent blood clots. This polymer-based sensor, which fits under compression stockings or bandages, works with a handheld reader to determine if the correct pressure is being applied to the body. This advancement is particularly valuable for post-orthopedic surgery patients, where maintaining the appropriate compression level is crucial to prevent DVT and other vascular complications.

Structural Shift Toward At-Home Compression Therapy

The rapid growth of home healthcare is emerging as a powerful driver of the compression therapy industry outlook. As healthcare systems globally face mounting pressure from demographic aging and rising chronic disease burdens, there is a structural shift toward moving treatment from hospital and clinical settings to the home environment. The compression therapy devices market is particularly well-suited to this transition, as modern pneumatic compression devices and compression garments can now deliver clinically effective treatment with minimal clinical supervision, enabling patients with lymphedema, DVT, and chronic venous insufficiency to manage their conditions independently.

Manufacturers are increasingly exploring AI-enabled compression technologies that improve pressure adjustment and treatment personalization, an emerging capability. This convergence of compression therapy with digital health technology is expanding the addressable patient population beyond those requiring clinical supervision, attracting younger demographics via wearable compression therapy devices, including athletes seeking accelerated recovery and frequent travelers managing DVT risk. The direct-to-consumer channel for compression therapy products is growing particularly rapidly, with online retail platforms enabling global reach for wearable compression brands at lower distribution costs than traditional medical device channels.

Restraint

Low Patient Adherence and Reimbursement Limitations in Key Markets

Despite strong clinical evidence for compression therapy's effectiveness in managing venous and lymphatic conditions, the market faces a significant restraint in the form of persistently low patient adherence rates. Clinical studies consistently show that 30-50% of patients prescribed compression stockings or garments do not use them as directed, primarily due to difficulties with application, discomfort during warm weather, aesthetic concerns, and a lack of perceived immediate benefit for chronic conditions. This adherence gap directly limits repeat purchase rates and constrains long-term revenue potential for manufacturers of graduated compression garments, which represent the largest product segment by volume.

Reimbursement limitations compound this challenge in several key markets. In the United States, Medicare and Medicaid coverage for compression garments remains inconsistent and subject to strict eligibility criteria, with many graduated compression stocking products excluded from standard reimbursement pathways entirely. The Lymphedema Treatment Act, signed into U.S. law in 2022, has partially addressed coverage gaps for lymphedema patients, but broader coverage for venous insufficiency and preventive applications remains limited. In European markets, reimbursement policies vary significantly by country and compression class, creating a fragmented commercial landscape that increases market access complexity for manufacturers operating across multiple geographies.

Together, these constraints help explain why the market's projected 5.7% CAGR, while healthy, is moderate relative to the scale of underlying clinical need. Despite increasing adoption of advanced compression devices, overall market growth remains moderate due to the mature penetration of traditional compression garments in developed markets and the reimbursement limitations described above, both of which cap the pace at which clinical need translates into purchasing volume.

Compression Therapy Market Trends & Opportunities

Smart Compression Therapy Devices Are Adding Connectivity and Digital Adherence Monitoring

Smart compression therapy devices are emerging as a distinct product category layered on top of conventional compression garments and pneumatic systems, incorporating Bluetooth connectivity, embedded pressure sensors, and mobile application integration that together provide real-time feedback on therapeutic efficacy. Digital adherence monitoring is a particularly significant capability within this category, since low patient adherence, is the market's single largest constraint on repeat purchasing and long-term revenue. A device that can log actual wear time and pressure delivery gives clinicians objective adherence data for the first time, rather than relying on patient self-report, potentially allowing earlier intervention when a patient is not following their prescribed regimen.

Home-Based Pneumatic Compression Therapy Is Shifting Care Away From Hospitals

Home-based pneumatic compression therapy is accelerating the broader shift from hospital and clinical settings to the home environment, extending it specifically into the pneumatic device category that has historically required more clinical oversight than static garments. Modern home-use pneumatic compression platforms increasingly incorporate remote patient monitoring capability, allowing a clinician to track a patient's usage patterns and treatment response without requiring an in-person visit. This is particularly significant for lymphedema and chronic venous insufficiency patients, who often require long-term, ongoing therapy where frequent clinical visits are both costly for the health system and burdensome for the patient.

Personalized Compression Therapy Is Moving Beyond Standardized Pressure Classes

Personalized compression therapy is emerging as an alternative to the standardized Class I, II, and III pressure classifications that have historically defined the compression stockings segment. Customized pressure levels, tailored to a specific patient's limb measurements, condition severity, and treatment goals rather than a generic class specification, are increasingly available through made-to-measure compression garments and adjustable pneumatic systems. Patient-specific compression garments address a documented driver of the adherence problem, since a poorly fitted standardized garment is both less comfortable and less clinically effective than one fitted to the individual, giving personalization a direct commercial rationale beyond premium positioning alone.

Segment Analysis

The global compression therapy market is segmented based on product, technique, application, distribution channel and region.

Compression Bandages Hold the Largest Product Share; Compression Stockings Are Widely Prescribed Across Graduated Pressure Classes

Compression bandages market segment, anchoring the compression therapy bandages market, held the largest market revenue share of approximately 27% in the year 2025. The growth of the compression bandages segment is due to their versatility, cost-effectiveness, and widespread use in treating a variety of conditions, including venous leg ulcers and acute injuries. Unlike fixed compression garments, bandages offer customizable pressure and can be adjusted based on the patient's condition, making them especially useful in chronic wound care, where graduated compression plays a critical role in promoting venous return and accelerating healing in venous leg ulcers specifically.

The compression stockings market spans products prescribed across graduated pressure classes I, II, and III corresponding to increasing severity of venous insufficiency, remain central to both post-surgical applications and long-term chronic venous disease management. Graduated compression stockings apply the highest pressure at the ankle, gradually decreasing up the leg, a design specifically engineered to support venous return against gravity, distinguishing them clinically from uniform-pressure alternatives. Post-surgical applications, particularly following orthopedic and vascular procedures, represent a distinct prescribing pathway from long-term venous insufficiency management, since post-surgical use is typically time-limited while chronic venous disease often requires indefinite, ongoing wear.

The segment is also benefiting from increasing awareness of evidence-based wound care protocols that recommend compression bandaging as a frontline therapy for managing chronic wounds. In September 2024, SUGAMA contributed to this trend by launching its Elastic Adhesive Bandage (EAB), designed to provide superior support, compression, and comfort. As part of the wider compression wraps market, this bandage features breathable, skin-friendly materials, strong adhesion, and high elasticity, suitable for diverse applications including medical recovery, athletic support, and joint stabilization.

Pneumatic Compression Devices: Intermittent and Sequential Systems Anchor Lymphedema Treatment and Home-Use Growth

The pneumatic compression devices market divides clinically into intermittent pneumatic compression (IPC), which applies uniform pressure in timed cycles primarily for DVT prophylaxis in hospitalized and post-surgical patients, and sequential compression devices, which inflate in a wave-like pattern from the foot upward, more closely mimicking the muscle pump action that drives natural venous return and making them particularly effective for lymphedema compression therapy. Lymphedema compression therapy is a core application for pneumatic devices specifically because the condition involves lymphatic fluid accumulation that static garments alone often cannot adequately mobilize, requiring the active, cyclical pressure that only pneumatic systems provide. Home-use adoption of pneumatic devices is accelerating as the structural shift toward at-home care extends into this historically more clinically supervised device category, supported by the remote monitoring capabilities.

By technique, static compression therapy holds the dominant share of the market at approximately 69% depending on the source, driven by the widespread use of compression garments, bandages, and stockings that deliver consistent passive pressure. Static compression is preferred for its ease of use, affordability, and suitability for long-term outpatient and home management of chronic venous conditions. Dynamic compression therapy, delivered through pneumatic devices that apply sequential or intermittent pressure, is the fastest-growing technique segment with a CAGR of 5.6%, supported by clinical evidence for superior outcomes in lymphedema management and DVT prevention. For instance, in March 2025, InventHelp Inventors introduced a new patent-pending applicator device that helps users apply compression stockings independently, improving adherence particularly among elderly patients.

Medical Versus Consumer and Wellness Applications Represent Increasingly Distinct Demand Pools

Medical applications, including DVT prevention devices, lymphedema management, and venous insufficiency treatment devices, remain the largest and most clinically established demand base for compression therapy, typically involving physician prescription, graduated pressure classes, and in many cases insurance or public reimbursement pathways. Consumer and wellness applications represent a distinct and faster-growing demand pool operating largely outside clinical prescription and reimbursement systems entirely: athletic recovery, fitness-oriented compression wear, and travel-related swelling management are purchased directly by consumers seeking performance or comfort benefits rather than treating a diagnosed medical condition. This distinction matters commercially because consumer and wellness products compete on brand, design, and direct-to-consumer marketing rather than clinical efficacy data and reimbursement coding, illustrated by October 2024's launch of Hyperice's Normatec Premier, a fully wireless dynamic air compression recovery device marketed directly to athletes and wellness enthusiasts rather than through medical channels, a go-to-market approach that would be unusual for a product positioned primarily for DVT prevention or lymphedema management.

Geographical Penetration

North America Compression Therapy Market: Rising Prevalence of Chronic Venous and Lymphatic Conditions

North America compression therapy market held a significant market revenue share of 43% in the year 2025, driven by the rising prevalence of chronic venous and lymphatic conditions, demographic aging, and continuous technological advancements in therapeutic devices. A key contributor to this trend is the sharp increase in peripheral artery disease (PAD), a condition that often necessitates compression therapy as part of its management. According to a research article published by Vascular Disease Management in April 2023, PAD prevalence in the U.S. has surged from 11.3 million in 1995 to an estimated 26 million in 2020, with projections showing it will reach 23.8 million by 2030.

Innovation in compression therapy devices is accelerating market expansion further. In October 2024, Tactile Medical introduced the next-generation Nimbl Pneumatic Compression Platform, specifically designed to address the needs of patients with lymphedema, making at-home therapy more accessible and improving patient adherence. With enhanced user experience and greater therapeutic efficiency, products like the Nimbl platform are setting new standards in the compression therapy landscape.

Europe Compression Therapy Market: Aging Population and Strong Manufacturer Presence Anchor Regional Demand

The Europe compression therapy market is anchored by a rapidly aging population and correspondingly high prevalence of chronic venous disease, combined with a deeply established culture of compression garment prescription that predates similar adoption levels in North America. The compression garments market and medical compression therapy sector enjoy particularly high clinical adoption across Germany, France, and the UK, where compression therapy has long been a first-line, guideline-recommended treatment for chronic venous insufficiency rather than a secondary option considered only after other treatments fail. Reimbursement frameworks vary meaningfully by country and compression class, a fragmentation, but several major European health systems, including Germany's statutory health insurance, provide more consistent coverage for prescribed medical compression garments than the U.S. Medicare system does, supporting sustained clinical utilization.

Europe is also home to several of the compression therapy systems industry's most established manufacturers, reflecting the region's deep clinical and manufacturing heritage in this category. Germany-based medi GmbH & Co. KG and Paul Hartmann AG, Austria-headquartered Juzo, and Sweden-based Essity Health & Medical maintain substantial European manufacturing and clinical distribution networks, giving the region a domestic supply base that most other markets rely on imports to serve. This concentration of manufacturing expertise, combined with strong clinical guideline support for compression therapy, positions Europe as a mature but structurally important market within the global compression therapy landscape.

Asia-Pacific Compression Therapy Market: High-Growth Region Driven by Aging Demographics and Rising Chronic Disease Prevalence

Asia-Pacific represents the fastest-growing regional market for compression therapy, driven by rapidly aging populations, rising prevalence of lifestyle-related vascular conditions, and expanding healthcare infrastructure across China, Japan, South Korea, India, and Southeast Asia. Japan and South Korea, with two of the world's most rapidly aging populations, represent mature and well-established compression therapy markets where clinical adoption is high and product sophistication is advanced. Japan in particular has a strong domestic medical device industry producing high-quality compression garments and pneumatic devices, supported by robust national health insurance coverage for venous and lymphatic conditions.

China is the highest-growth priority market in Asia-Pacific with a CAGR of 7.8%, driven by an estimated 233 million people living with diabetes as of 2023, the world's largest diabetic population, combined with a rapidly aging demographic and growing awareness of DVT risk factors associated with increased long-haul air travel and sedentary urban lifestyles. Chinese healthcare authorities have been expanding chronic disease management programs that include compression therapy protocols, and domestic manufacturers are scaling production of affordable compression garments targeting the vast lower-tier city consumer base. India presents significant long-term potential, with its large and underpenetrated vascular disease patient population beginning to gain access to compression therapy through expanding pharmacy retail networks, online health platforms, and growing clinical awareness among cardiologists and vascular surgeons of the cost-effectiveness of compression-based DVT prevention protocols.

Key Developments

•        In February 2026, Tactile Medical announced the acquisition of LymphaTech to strengthen its lymphedema management portfolio. LymphaTech's technology enhances Tactile Medical's capabilities in advanced compression therapy solutions and expands its technological reach in lymphatic care, reinforcing its position as a leading provider of at-home pneumatic compression therapy for patients with lymphedema and related chronic conditions.

•        In September 2025, AIROS® Medical, Inc., a medical technology manufacturer and designer specializing in compression therapy devices that treat lymphedema and venous complications, today announced the launch of expanded sizing for its truncal garments. These larger garment modelsgrant more patients living with lymphedema-related abdominal and pelvic swelling access to pneumatic compression device-driven compression therapy that reduces edema and pain.

•        In November 2024, Cardinal Health launched the Kendall SCD SmartFlow Compression System, an advanced medical device designed to enhance venous thromboembolism prevention in hospitalized patients. The system provides sequential compression therapy, which helps reduce the risk of deep vein thrombosis and pulmonary embolism.

•        In October 2024, Hyperice, a global high-performance wellness brand, announced the launch of Normatec Premier, the most advanced and fully integrated dynamic air compression therapy device to date, offering athletes and wellness enthusiasts a comprehensive recovery experience through a fully wireless approach.